Patent cliffs aren’t just a legal event—they’re a supply-chain event.
When a blockbuster drug’s exclusivity ends, the industry often treats it like a spreadsheet problem: update forecasts, watch for generic launches, and move on. But the real impact …

The FDA Orange Book isn’t just a database—it’s a playbook.
Generic drug makers don’t “wait for patents to expire” in the abstract. They engineer timing. They map risk. And they build a case—often long before the market window opens.
That’s the real s…

Biopharma hiring is broken in a way that’s easy to miss: we keep treating IP as a standalone function—when, in practice, it’s an operating system.
In other words, the “right” IP talent isn’t just about knowing patents. It’s about understanding how an I…

The generic cliff doesn’t “hit.” It’s engineered around.
For years, investors have treated expiring drug patents like a predictable calendar event: once exclusivity ends, generics rush in, prices fall, and revenue curves bend downward. But the realit…

Patent thickets are the quiet tax on innovation—and they’re getting thicker around biologic blockbusters.
If you’ve ever wondered why some breakthrough medicines seem to stay “just out of reach” for years after their first approvals, the answer often…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most companies don’t lose on patents because they “didn’t try.” They lose because they tried too late.
By the time a generic challenger, investor, or licensing partner is deep into …

Most teams treat formulation patents like a black box. That’s why they miss the design-around window.
In pharma, the “real” competitive advantage often isn’t the active ingredient—it’s the formulation. The release profile, stability, solubility, manufa…

Russia’s latest VED/SSM listing isn’t just another regulatory update—it’s a live-fire signal for how generics will (and won’t) enter the market.
Here’s the agitation: in pharma, timing is everything, but most teams still treat “patent expiry” like a ca…

Pharma pipelines don’t fail in the lab. They fail in the courtroom.
That’s the uncomfortable truth behind Freedom to Operate (FTO) work—and why the best teams treat it like a strategic discipline, not a one-time legal checkbox.
In a world where patents…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Differentiation—and Defense
In generic drug land, the default playbook is simple: file an ANDA, win on price, and let the market do the rest.
But that playbook is increasingly crowded—and …